Faeth Therapeutics, Inc. (FTH) Stock Price & Analysis

Faeth Therapeutics, Inc. (FTH) closed at USD 19.2 on Wednesday, October 28, 2026, up 0.47% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 19.11; the Oct 28, 2026 session ranged USD 18.72–20.98 on volume of 417,676 shares. Market capitalization is $496.14M, with a 52-week range of USD 7.45–42.14 (NCM). Source: Nexqual, retrieved October 29, 2026 at 05:59 UTC.

Also available as compact Markdown for AI agents: nexqual.com/FTH.md

Key facts (FTH)

• Insider open-market sales, last ~7 months: 5 Form 4 filings, $1.7M; 5 not under a Rule 10b5-1 plan ($1.7M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 7 Form 4 filings, $2.5M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.81 on a 1–5 scale) (16 analysts), mean target USD 55.38 (range 40–70).
• Total return with dividends: 1Y +104.8% vs S&P 500 +13.6%; 5Y -89.0% vs S&P 500 +79.8%.
• Next earnings: 2026-11-03, EPS estimate USD -0.72, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (FTH)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (FTH)

P/B 2.9x · FCF yield -6.83% · Earnings yield -39.41%

Insider sales (SEC Form 4, open-market, last ~7 months) (FTH)

0 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (FTH)

7 purchases, $2.5M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (FTH)

Consensus Buy (mean 1.81 on a 1–5 scale), 16 analysts; mean target USD 55.38 (low 40, high 70).

Rating changes, last 120 days:

Total return (dividends reinvested) (FTH)

FTH earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

FTH recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

FTH suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 30, 2026.

FTH company outlook (results filed Aug 4, 2026)

• “We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer, which is expected by year-end." Mr.”
• “PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), with topline data anticipated in the second half of 2026.”
• “PIKTOR is also being evaluated in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027.”

Quoted word-for-word from the SEC 8-K results press release.

FTH analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 05:59 UTC)

Technical Analysis (FTH)

Nexqual's technical model rates FTH "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 05:59 UTC.

Analyst Ratings (FTH)

Wall Street analysts rate FTH "Buy" based on 16 analysts, with a mean price target of USD 55.38 (range USD 40–70), per Nexqual as of October 29, 2026 at 05:59 UTC.

Earnings (FTH)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 05:59 UTC.

Financials & Fundamentals (FTH)

Source: Nexqual, October 29, 2026 at 05:59 UTC.

Financial Health Score (FTH)

Nexqual rates Faeth Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 05:59 UTC.

Ownership (FTH)

Source: Nexqual, October 29, 2026 at 05:59 UTC.

Leadership (FTH)

Faeth Therapeutics, Inc. is led by Anand Parikh Esq., CEO, President & Chair, per Nexqual as of October 29, 2026 at 05:59 UTC.

Major Backers & Investors (FTH)

Notable institutional backers of Faeth Therapeutics, Inc. include Montanova Capital LLC, Avoro Capital Advisors LLC, Baker Bros. Advisors, LP, according to Nexqual as of October 29, 2026 at 05:59 UTC.

Active Investors

Source: Nexqual, October 29, 2026 at 05:59 UTC.

From Faeth Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• We seek to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties.
• Our platform seeks to identify and exploit potential cancer cell vulnerabilities to create integrated treatment regimens to deny tumors the signaling pathways and nutrients they depend upon to proliferate.
• Prior to the Acquisition, we developed a portfolio of intellectual property relating to our TMAb conditionally active biologic platform and product candidates.

Partnerships

• We are party to a license agreement with Takeda that was originally entered into in March 2019, or the Takeda License Agreement, between Takeda and Petra Pharma Corporation, or Petra, which was subsequently assigned by Petra to Ravenna Pharmaceuticals, Inc., or Ravenna, and later acquired by Faeth in February 2021 in connection with its acquisition of assets related to serabelisib pursuant to an asset purchase agreement with Ravenna.
• We are party to an amended and restated asset purchase agreement with Millennium Takeda that was originally entered into in May 2023, or the Millennium Takeda Asset Purchase Agreement, between Millennium Takeda and Calithera Biosciences, Inc., or Calithera, which was acquired by Faeth in May 2023 in connection with its acquisition of assets related to sapanisertib pursuant to an asset purchase agreement with Calithera.

Legal & Regulatory Risks (Item 1A, quoted)

• We rely, and expect to continue to rely, on third parties to conduct the preclinical and clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory requirements.
• Our business is highly dependent on the success of our product candidates that we advance into the clinic, particularly PIKTOR. All of our product candidates, including PIKTOR, will require significant additional preclinical, clinical and manufacturing development before we may be able to seek regulatory approval for and launch a product commercially and we may not be successful in our efforts.
• We currently rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If those third parties do not perform satisfactorily, including failing to meet deadlines for the completion of such clinical trials or failing to comply with regulatory requirements, we may be unable to obtain regulatory approval for our product candidates.
• Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 05:59 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt